Tumor-Targeted Delivery of a TLR7 Agonist by Site-Specific Antibody-Drug Conjugate

Time: 2:20 pm
day: Day Two


• TLR agonist therapies are largely restricted to intratumoral administration due to systemic toxicity

• Ambrx has developed a platform to enable tumor targeted delivery of a TLR7 agonist via homogenous,
site-specific antibody-drug conjugate (ADC)

• Review how tumor-targetedTLR7 agonist ADCs induce potent anti-tumor immune responses and outperform systemically administered TLR7 agonist